Treatment with eptinezumab (Vyepti)

The preparation

Vyepti is administered as an infusion. Vyepti is specifically developed to prevent migraine and is approved for adults who have at least 4 attacks per month.

Effect

It is known that CGRP (calcitonin gene-related peptide), which is produced in our nervous system, plays an active role in a migraine attack.

Vyepti works by binding specifically to and blocking the activity of the CGRP molecule in the brain. This can reduce the number and severity of your migraine attacks.

Since Vyepti is administered directly into the bloodstream, the maximum concentration in the blood is reached after just 30 minutes.

Vyepti has a half-life of approximately 27 days.

Side effects

Respiratory tract irritation, fatigue, and rarely allergic reactions such as difficulty breathing, weak pulse, drop in blood pressure, itching, and/or swelling of the lips and tongue. As there is an enhanced reporting requirement for Vyepti, it is important that you inform your healthcare provider if you experience any side effects other than those described.

Precautions

You should not be treated with Vyepti if you have certain types of cardiovascular disease.

Vyepti must not be used by pregnant or breastfeeding women.

You must discontinue your treatment with Vyepti at least 5 months before trying to become pregnant.

Before starting treatment

Blood pressure is checked.

What dosage should be taken?

The standard dose is 100 mg of Vyepti mixed with 100 ml of saline per session. If necessary, the dose can be gradually increased to a maximum of 300 mg IV every 12 weeks.

How is Vyepti administered?

Treatment takes place at the clinic every 12 weeks. Vyepti is administered intravenously, meaning via a drip through a small needle placed in a vein, typically on the back of the hand or in the crook of the elbow. The infusion itself is given over half an hour, followed by a 50 ml saline flush.

You can drive home immediately after the treatment is finished.